Highlights Vor Biopharma Inc.

Equities

VOR

US9290331084

Delayed Nasdaq Other stock markets 12:40:16 28/06/2024 am IST			5-day change	1st Jan Change
1.145 ^USD	-0.43%		-5.00%	-49.33%

13/06	Voyager Therapeutics Names Nathan Jorgensen as Finance Chief	MT
10/06	Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/03	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Vor Bio Doses First AML Patient with VCAR33	18/01	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	10/11	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	02/11	CI
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101	09/23/09	CI
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Vor Biopharma Inc. Presents Clinical Data from VBP101	16/23/16	CI
PureTech founded entity Vor Bio first AML patient gets transplant	08/22/08	AN
Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel and Tolerated Mylotarg(Tm)	07/22/07	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Vor Bio Announces Opening of its New In-House Clinical Manufacturing Facility in Cambridge, MA	28/22/28	CI
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA	10/22/10	CI
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Vor Biopharma, Akron BioProducts Partner to Develop Nucleases	22/22/22	MT
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases	22/22/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vor Biopharma Inc.

Equities

VOR

US9290331084

Highlights

Filters